OBJECTIVE: The goals were to identify the blood pressures of extremely low gestational age newborns that prompt intervention, to identify other infant characteristics associated with receipt of therapies intended to increase blood pressure, and to assess the interinstitutional variability in the use of these therapies. METHODS: The cohort included 1507 extremely low gestational age newborns born at 23 weeks to 27 weeks of gestation, at 14 institutions, between March 2002 and August 2004; 1387 survived the first postnatal week. Blood pressures were measured as clinically indicated. Interventions were grouped as any treatment (ie, vasopressor and/or fluid boluses of >10 mL/kg) and vasopressor treatment, and logistic regression analyses were performed. RESULTS: At each gestational age, the lowest mean arterial pressures in treated and untreated infants tended to increase with advancing postnatal age. Infants who received any therapy tended to have lower mean arterial pressures than infants who did not, but uniform thresholds for treatment were not apparent. The proportion of infants receiving any treatment decreased with increasing gestational age from 93% at 23 weeks to 73% at 27 weeks. Treatment nearly always began during the first 24 hours of life. Lower gestational age, lower birth weight, male gender, and higher Score for Neonatal Acute Physiology-II values were associated with any treatment and vasopressor treatment. Institutions varied greatly in their tendency to offer any treatment and vasopressor treatment. Neither the lowest mean arterial pressure on the day of treatment nor other characteristics of the infants accounted for center differences in treatment. CONCLUSIONS: Blood pressure in extremely premature infants not treated for hypotension increased directly with both increasing gestational age and postnatal age. The decision to provide treatment was associated more strongly with the center where care was provided than with infant attributes.
OBJECTIVE: The goals were to identify the blood pressures of extremely low gestational age newborns that prompt intervention, to identify other infant characteristics associated with receipt of therapies intended to increase blood pressure, and to assess the interinstitutional variability in the use of these therapies. METHODS: The cohort included 1507 extremely low gestational age newborns born at 23 weeks to 27 weeks of gestation, at 14 institutions, between March 2002 and August 2004; 1387 survived the first postnatal week. Blood pressures were measured as clinically indicated. Interventions were grouped as any treatment (ie, vasopressor and/or fluid boluses of >10 mL/kg) and vasopressor treatment, and logistic regression analyses were performed. RESULTS: At each gestational age, the lowest mean arterial pressures in treated and untreated infants tended to increase with advancing postnatal age. Infants who received any therapy tended to have lower mean arterial pressures than infants who did not, but uniform thresholds for treatment were not apparent. The proportion of infants receiving any treatment decreased with increasing gestational age from 93% at 23 weeks to 73% at 27 weeks. Treatment nearly always began during the first 24 hours of life. Lower gestational age, lower birth weight, male gender, and higher Score for Neonatal Acute Physiology-II values were associated with any treatment and vasopressor treatment. Institutions varied greatly in their tendency to offer any treatment and vasopressor treatment. Neither the lowest mean arterial pressure on the day of treatment nor other characteristics of the infants accounted for center differences in treatment. CONCLUSIONS: Blood pressure in extremely premature infants not treated for hypotension increased directly with both increasing gestational age and postnatal age. The decision to provide treatment was associated more strongly with the center where care was provided than with infant attributes.
Authors: Beau Batton; Lei Li; Nancy S Newman; Abhik Das; Kristi L Watterberg; Bradley A Yoder; Roger G Faix; Matthew M Laughon; Barbara J Stoll; Krisa P Van Meurs; Waldemar A Carlo; Brenda B Poindexter; Edward F Bell; Pablo J Sánchez; Richard A Ehrenkranz; Ronald N Goldberg; Abbot R Laptook; Kathleen A Kennedy; Ivan D Frantz; Seetha Shankaran; Kurt Schibler; Rosemary D Higgins; Michele C Walsh Journal: Pediatrics Date: 2013-05-06 Impact factor: 7.124
Authors: Christopher J Rhee; Cristine Sortica da Costa; Topun Austin; Ken M Brady; Marek Czosnyka; Jennifer K Lee Journal: Pediatr Res Date: 2018-09-08 Impact factor: 3.756
Authors: Matthew Laughon; Carl Bose; Elizabeth N Allred; T Michael O'Shea; Richard A Ehrenkranz; Linda J Van Marter; Alan Leviton Journal: Arch Dis Child Fetal Neonatal Ed Date: 2010-08-05 Impact factor: 5.747
Authors: Alisse K Hauspurg; Elizabeth N Allred; Deborah K Vanderveen; Minghua Chen; Francis J Bednarek; Cynthia Cole; Richard A Ehrenkranz; Alan Leviton; Olaf Dammann Journal: Neonatology Date: 2010-07-30 Impact factor: 4.035
Authors: Matthew Laughon; Michael T O'Shea; Elizabeth N Allred; Carl Bose; Karl Kuban; Linda J Van Marter; Richard A Ehrenkranz; Alan Leviton Journal: Pediatrics Date: 2009-07-20 Impact factor: 7.124
Authors: I Nicholas Olomu; Jonathan L Hecht; Andrew O Onderdonk; Elizabeth N Allred; Alan Leviton Journal: Pediatrics Date: 2009-05 Impact factor: 7.124